Matthew K Howe
Overview
Explore the profile of Matthew K Howe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howe M, Dowdell K, Kuehn H, Li Q, Hart G, Garabedian D, et al.
J Infect Dis
. 2020 May;
222(7):1170-1179.
PMID: 32386415
Background: Chronic active Epstein-Barr virus (CAEBV) presents with high levels of viral genomes in blood and tissue infiltration with Epstein-Barr virus (EBV)-positive lymphocytes. The pathogenesis of CAEBV is poorly understood....
2.
Howe M, Dowdell K, Roy A, Niemela J, Wilson W, McElwee J, et al.
Front Immunol
. 2019 Sep;
10:2000.
PMID: 31507602
Interleukin-2-inducible T cell kinase (ITK) is critical for T cell signaling and cytotoxicity, and control of Epstein-Barr virus (EBV). We identified a patient with a novel homozygous missense mutation (D540N)...
3.
Howe M, Speer B, Hughes P, Loiselle D, Vasudevan S, Haystead T
Antiviral Res
. 2016 Apr;
130:81-92.
PMID: 27058774
An estimated three billion people are at risk of Dengue virus (DENV) infection worldwide and there are currently no approved therapeutic interventions for DENV infection. Due to the relatively small...
4.
Howe M, Bodoor K, Carlson D, Hughes P, Alwarawrah Y, Loiselle D, et al.
Chem Biol
. 2014 Dec;
21(12):1648-59.
PMID: 25500222
Inducible Hsp70 (Hsp70i) is overexpressed in a wide spectrum of human tumors, and its expression correlates with metastasis, poor outcomes, and resistance to chemotherapy in patients. Identification of small-molecule inhibitors...
5.
Nelson E, Wardell S, Jasper J, Park S, Suchindran S, Howe M, et al.
Science
. 2013 Nov;
342(6162):1094-8.
PMID: 24288332
Hypercholesterolemia is a risk factor for estrogen receptor (ER)-positive breast cancers and is associated with a decreased response of tumors to endocrine therapies. Here, we show that 27-hydroxycholesterol (27HC), a...
6.
Shi Y, Han J, Tennakoon J, Mehta F, Merchant F, Burns A, et al.
Mol Endocrinol
. 2012 Dec;
27(2):280-95.
PMID: 23250485
Androgens regulate both the physiological development of the prostate and the pathology of prostatic diseases. However, the mechanisms by which androgens exert their regulatory activities on these processes are poorly...
7.
Nelson E, DuSell C, Wang X, Howe M, Evans G, Michalek R, et al.
Endocrinology
. 2011 Sep;
152(12):4691-705.
PMID: 21933863
Osteoporosis and age-related bone loss are important public health concerns. Therefore, there is a high level of interest in the development of medical interventions and lifestyle changes that reduce the...
8.
Frigo D, Howe M, Wittmann B, Brunner A, Cushman I, Wang Q, et al.
Cancer Res
. 2010 Nov;
71(2):528-37.
PMID: 21098087
While patients with advanced prostate cancer initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years. Although hormone-refractory disease is unresponsive to androgen-deprivation,...